TY - JOUR
T1 - Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition
AU - Tsilidis, K. K.
AU - Allen, N. E.
AU - Key, T. J.
AU - Dossus, L.
AU - Lukanova, A.
AU - Bakken, K.
AU - Lund, E.
AU - Fournier, A.
AU - Overvad, K.
AU - Hansen, L.
AU - Tjønneland, A.
AU - Fedirko, V.
AU - Rinaldi, S.
AU - Romieu, I.
AU - Clavel-Chapelon, F.
AU - Engel, P.
AU - Kaaks, R.
AU - Schütze, M.
AU - Steffen, A.
AU - Bamia, C.
AU - Trichopoulou, A.
AU - Zylis, D.
AU - Masala, G.
AU - Pala, V.
AU - Galasso, R.
AU - Tumino, R.
AU - Sacerdote, C.
AU - Bueno-De-Mesquita, H. B.
AU - Van Duijnhoven, F. J B
AU - Braem, M. G M
AU - Onland-Moret, N. C.
AU - Gram, I. T.
AU - Rodríguez, L.
AU - Travier, N.
AU - Sánchez, M. J.
AU - Huerta, J. M.
AU - Ardanaz, E.
AU - Larrãaga, N.
AU - Jirström, K.
AU - Manjer, J.
AU - Idahl, A.
AU - Ohlson, N.
AU - Khaw, K. T.
AU - Wareham, N.
AU - Mouw, T.
AU - Norat, T.
AU - Riboli, E.
PY - 2011/10/25
Y1 - 2011/10/25
N2 - Background: It is well established that parity and use of oral contraceptives reduce the risk of ovarian cancer, but the associations with other reproductive variables are less clear. Methods: We examined the associations of oral contraceptive use and reproductive factors with ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 327 396 eligible women, 878 developed ovarian cancer over an average of 9 years. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard models stratified by centre and age, and adjusted for smoking status, body mass index, unilateral ovariectomy, simple hysterectomy, menopausal hormone therapy, and mutually adjusted for age at menarche, age at menopause, number of full-term pregnancies and duration of oral contraceptive use. Results: Women who used oral contraceptives for 10 or more years had a significant 45% (HR, 0.55; 95% CI, 0.41-0.75) lower risk compared with users of 1 year or less (P-trend, 52 vs ≤45 years: HR, 1.46; 95% CI, 1.06-1.99; P-trend, 0.02). Age at menarche, age at first full-term pregnancy, incomplete pregnancies and breastfeeding were not associated with risk. Conclusion: This study shows a strong protective association of oral contraceptives and parity with ovarian cancer risk, a higher risk with a late age at menopause, and no association with other reproductive factors.
AB - Background: It is well established that parity and use of oral contraceptives reduce the risk of ovarian cancer, but the associations with other reproductive variables are less clear. Methods: We examined the associations of oral contraceptive use and reproductive factors with ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 327 396 eligible women, 878 developed ovarian cancer over an average of 9 years. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard models stratified by centre and age, and adjusted for smoking status, body mass index, unilateral ovariectomy, simple hysterectomy, menopausal hormone therapy, and mutually adjusted for age at menarche, age at menopause, number of full-term pregnancies and duration of oral contraceptive use. Results: Women who used oral contraceptives for 10 or more years had a significant 45% (HR, 0.55; 95% CI, 0.41-0.75) lower risk compared with users of 1 year or less (P-trend, 52 vs ≤45 years: HR, 1.46; 95% CI, 1.06-1.99; P-trend, 0.02). Age at menarche, age at first full-term pregnancy, incomplete pregnancies and breastfeeding were not associated with risk. Conclusion: This study shows a strong protective association of oral contraceptives and parity with ovarian cancer risk, a higher risk with a late age at menopause, and no association with other reproductive factors.
KW - cohort study
KW - oral contraceptive use
KW - ovarian cancer
KW - reproductive history
UR - http://www.scopus.com/inward/record.url?scp=80055013415&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80055013415&partnerID=8YFLogxK
U2 - 10.1038/bjc.2011.371
DO - 10.1038/bjc.2011.371
M3 - Article
C2 - 21915124
AN - SCOPUS:80055013415
SN - 0007-0920
VL - 105
SP - 1436
EP - 1442
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 9
ER -